Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Addition of obinutuzumab after one year of combined acalabrutinib and venetoclax is safer and effective than early obinutuzumab in a randomized Phase II trial for treatment naïve CLL

Mahesh Swaminathan, Philip Thompson, Jan Burger et al. Nov 03, 2025 pp. 681-681 10.1182/blood-2025-681

Abstract Introduction: The treatment landscape of chronic lymphocytic leukemia (CLL) includes Bruton tyrosine kinase inhibitors (BTKi), B-ce...

IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia

Matthew Connor, Wei-Ting Hwang, Saar Gill et al. Nov 03, 2025 pp. 812-812 10.1182/blood-2025-812

Abstract Introduction Despite high complete remission (CR) rates after CD19-directed chimeric antigen receptor (CAR) T cells for relapsed/re...

Paroxysmal cold hemoglobinuria associated with monoclonal b-cell lymphocytosis in an elderly patient: A rare case report

Summiya Nasim, Matthew Bartock Nov 03, 2025 pp. 6439-6439 10.1182/blood-2025-6439

Abstract Introduction: Paroxysmal cold hemoglobinuria (PCH) is a rare cause of autoimmune hemolytic anemia...

Transcriptional programming by GATA3 regulates CD4+ T cell GM-CSF production in the gastrointestinal tract during graft versus host disease

Mark Castleberry, Alison Moe, Jonathan Florentin et al. Nov 03, 2025 pp. 158-158 10.1182/blood-2025-158

Abstract Acute graft versus host disease (GVHD) of the gastrointestinal (GI) tract is a major complication of allogeneic hematopoietic stem...

Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma

Heinz Ludwig, Evangelos Terpos, Mario Boccadoro et al. Nov 03, 2025 pp. 7558-7558 10.1182/blood-2025-7558

Abstract External Control arms (ECAs) help to evaluate the effectiveness of a new treatment by comparing its outcomes with those of a simila...

Integrated multi-omic profiling reveals two biologically distinct subgroups of splenic marginal zone lymphoma with prognostic relevance

Helen Parker, Ben Stevens, Amatta Mirandari et al. Nov 03, 2025 pp. 353-353 10.1182/blood-2025-353

Abstract Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy mainly affecting the spleen, bone marrow, and peripheral blood. C...

Trends and disparities in agranulocytosis-related mortality in adults aged ≥ 65 yearsin the United States from 1999 to 2023: A CDC wonder database analysis

Ahmed Raza, Anas nasir, Muhammad Ali et al. Nov 03, 2025 pp. 6544-6544 10.1182/blood-2025-6544

Abstract Introduction: Agranulocytosis is a life-threatening hematologic disorder characterized by a severe reduction in neutrophils, which...

Genetic predispositions in children with primary immunodeficiency and lymphoma: Experience from king hussein cancer center

Mayada Abu Shanap, Duaa Zandaki, Zaid Abdel Rahman et al. Nov 03, 2025 pp. 8088-8088 10.1182/blood-2025-8088

Abstract Introduction: Primary immunodeficiencies (inborn errors of immunity) confer susceptibility to recurrent infections and malignancies...

Trends in aplastic anemia mortality among older adults with sepsis in the United States, 1999–2024: A CDC wonder database analysis

Muhammad Shaheer Bin Faheem, Syed Tawassul Hassan, Janta Ukrani et al. Nov 03, 2025 pp. 6736-6736 10.1182/blood-2025-6736

Abstract Background: Aplastic anemia is a rare but life-threatening hematologic disorder, with sepsis often acting as a critical contributin...

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Andrew Kuykendall, Douglas Tremblay, Anthony Hunter et al. Nov 03, 2025 pp. 5600-5600 10.1182/blood-2025-5600

Abstract Introduction JAK inhibition is the basis of treatment for most patients (pts) with myelofibrosis (MF). Early JA...

Hematopoietic architecture drives biological and metabolic heterogeneity and predicts treatment-free remission outcomes in chronic myeloid leukemia

Isabelle De Araujo, Mathilde Marlas, Marie-Laure Nicolau et al. Nov 03, 2025 pp. 3787-3787 10.1182/blood-2025-3787

Abstract Introduction Hematopoiesis is a series of physiological processes that ensure the continuous production of blood cells and that is b...

Clonal evolution and risk assessment in myelodysplastic syndromes (MDS): A prospective Study of dynamic IPSS-m validation and evolutionary trajectory modeling by the italian MDS foundation (FISIM)

Luca Lanino, Matteo Zampini, Ivan Civettini et al. Nov 03, 2025 pp. 3842-3842 10.1182/blood-2025-3842

Abstract Background Myelodysplastic syndromes (MDS) are associated with an increased risk of progression to acute myeloid leukemia (AML). Dis...

Temporal trends in overall survival among patients with high-risk MDS: Insights from the spanish MDS registry (RESMD)

Ana Alfonso-Pierola, Marina Diaz Beya, Teresa Bernal et al. Nov 03, 2025 pp. 3868-3868 10.1182/blood-2025-3868

Abstract Background: High-risk myelodysplastic syndromes (HR-MDS) are associated with poor survival outcomes. Although the introduction of hy...

High-accuracy, transfusion-aware machine learning pipeline for hemoglobin genotype classification with shap-based interpretability

Jonathan Wade, Jedrzej Konarkowski, Varsha Bhat et al. Nov 03, 2025 pp. 4743-4743 10.1182/blood-2025-4743

Abstract Background: Clinical management for individuals with sickle cell disease (SCD) varies by genotype, but accurate genotyping remains...

Evaluation of levofloxacine as antibiotic prophylaxis in MDS and AML patients treated with azacitidine: Results from the randomized open-label phase III azabac study

Juliette Pénichoux, Stephane Cheze, Wala Najar et al. Nov 03, 2025 pp. 3846-3846 10.1182/blood-2025-3846

Abstract Introduction The incidence of febrile neutropenia in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patients is hig...

Real-world outcomes and a novel prognostic assessment model for high-risk acute promyelocytic leukemia receiving all-trans retinoid acid and arsenic trioxide dual induction based on lasso-cox regression

Kai Shen, Chenlu Yang, Hongbing Ma Nov 03, 2025 pp. 1603-1603 10.1182/blood-2025-1603

Abstract Introduction: High-risk (HR) acute promyelocytic leukemia (APL) remains a challenge due to early death (ED) and relapse. All-trans...

Malnutrition: An underrecognized comorbidity in hematologic malignancies in a single institution review of nutrition referrals

Sean Bowden, Jenna Laidley, Robert Yuan et al. Nov 03, 2025 pp. 6400-6400 10.1182/blood-2025-6400

Abstract Background: Unintentional weight loss is a common presenting symptom of malignancy. This is often multifactorial, but arises in par...

A healthy volunteer study with lomonitinib predicts pharmacokinetics and pharmacodynamics in a relapsed refractory AML study

John Byrd, Brian Ledwith, Fraser Pickersgill et al. Nov 03, 2025 pp. 6781-6781 10.1182/blood-2025-6781

Abstract Background. Lomonitinib is a highly potent and selective pan-FLT3/ IRAK4 inhibitor derived from a novel in silico modeling approach...

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Austin Kim, Peter Riedell, Christine Ryan et al. Nov 03, 2025 pp. 664-664 10.1182/blood-2025-664

Abstract Background With the advent of effective targeted therapy, there is growing interest in chemotherapy-free regimens in patients (pts)...

Fetal hemoglobin dysregulation in inherited and acquired bone marrow failure syndromes

Victoria Heigh, Maymona Abdelmagid, Laura Ongie et al. Nov 03, 2025 pp. 6750-6750 10.1182/blood-2025-6750

Abstract Introduction: Inherited & acquired bone marrow failure syndromes (BMFS) have “stress erythropoiesis” with macrocytic anemia, el...

Low hematologic event-free survival with age in shwachman-diamond syndrome

Kasiani Myers, Jean Donadieu, Benjamin Goldberg et al. Nov 03, 2025 pp. 748-748 10.1182/blood-2025-748

Abstract Background: Shwachman Diamond syndrome (SDS) is characterized by bone marrow failure (BMF) and an increased risk of myeloid and lym...

Azacitidine and luspatercept metronomic therapy for intermediate- to high-risk myelodysplastic syndrome: A prospective single-center phase II clinical trial

Chenlu Yang, Qing Li, Yu Wu Nov 03, 2025 pp. 5625-5625 10.1182/blood-2025-5625

Abstract Introduction: Although hypomethylating agents (HMA) have improved outcomes in higher-risk myelodysplastic syndr...

Real-world duration of therapy with erythropoietic stimulating agents is predictive of overall survival in Myelodysplastic Syndromes (MDS)

Robert Reid, Rosa Banuelos, Lisa Herms et al. Nov 03, 2025 pp. 7366-7366 10.1182/blood-2025-7366

Abstract BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are a cornerstone of supportive care for anemia in lower-r...

A single-centre comparison of thiotepa-treosulfan versus thiotepa-busulfan based conditioning regimens in adults with haematological malignancies undergoing allogeneic haematopoietic stem cell transplant.

Kye Ling Wong, Tze Wei Chan, Chieh Hwee Ang et al. Nov 03, 2025 pp. 5982-5982 10.1182/blood-2025-5982

Abstract Introduction Choice of conditioning chemotherapy plays a crucial part in haematopoietic stem cell transplantation (HSCT) outcomes....

Impact of CAR-T cells expansion and tumor burden on the outcome after inotuzumab ozogamicin as bridging therapy in pediatric and young adult patients with relapse/refractory acute lymphoblastic leukemia.

Patricia Alcalde-Mellado, Victoria Ruiz-Maldonado, Javier Delgado Serrano et al. Nov 03, 2025 pp. 2324-2324 10.1182/blood-2025-2324

Abstract Introduction: Bridging therapy (BT) before treatment with tisagenlecleucel (tisa) in patients with relapsed/refractory B-cell acute...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page